FM-VP4, is a novel hydrophilic phytostanol analogue representing a new class in cholesterol-lowering drugs called cholesterol absorption inhibitors. FM-VP4 has been shown to inhibit cholesterol absorption and to lower plasma... Additional experiments suggest that FM-VP4 can reduce plasma LDL cholesterol levels and triglyceride levels, reduce weight gain and exert a anti-atherosclerosis effect.
- Mechanism
- Curator reviewed
FM VP4 is thought to bind competitively with cholesterol to MDR1 resulting in a synergistic decrease in cholesterol accumlation. Others have suggested that FM VP4 may act by inhibiting a transporter that mediates intestinal absorption of cholesterol. One study indicates that FM-VP4 inhibits cholesterol accumulation within IEC-6 cells and is most effective at equimolar concentrations with cholesterol, further suggesting that the action of FM-VP4 is likely at the cell surface and not elicited intracellularly.
- Primary indication
- Investigated for use/treatment in hyperlipidemia and cancer/tumors (unspecified).Curator reviewed
- Also known as
- Disodium ascorbyl phytostanol phosphates
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with FM-VP4, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account